Indiana Clinical Trials

A listing of Indiana clinical trials actively recruiting patient volunteers.

Indiana is about more than swashbuckling archaeologists. The capital, Indianapolis, is home to the famous Indianapolis Motor Speedway and Indy 500. Other great cities in the state include Evansville, Fort Wayne, and Bloomington. Indiana is one of the nation's leaders in the automotive industry and has seen some of the strongest manufacturing job growth nationwide. Oddly enough, it is also one of the top states in producing professional basketball players. Those seeking quality healthcare in Indiana have lots of options, including Methodist Hospital in Indianapolis, part of Indiana University Health. It has the largest neuroscience critical care unit in America.

Search by Name
Search
Filter by Condition
1349 trials found

Engaging Families to Improve the Care of Patients With Hypospadias

NCT05056311

Reconstructive surgery is advocated for most children with hypospadias, a condition in which the pee hold is not in the correct place on the penis, to prevent potentially serious cosmetic and functional problems. Parents faced with a decision about hypospadias repair encounter an irreversible choice with potentially lifelong consequences. Recent studies have identified decisional conflict (DC) and decisional regret (DR) as a significant problem for parents. Several recent guidelines on complex u ...

Conditions: Hypospadias
Phase: Not Applicable

Clinical Evaluation of Spherical Soft Contact Lenses, Toric Soft Contact Lenses and Spectacles in Low Astigmats

NCT05056870

This will be a 5-visit, randomized, partially single-masked, bilateral wear, dispensing, 2-treatment × 2-period crossover study with spectacle-wear washout and wash-in periods.

Conditions: Visual Acuity
Phase: Not Applicable

SaliPen Human Factors Study for OTC Labeling

NCT05058430

This Human Factors Validation Testing will assess user interactions to verify the capability of potential users to assess if the study product fits their needs and if they can use it correctly based on the provided Information For User (IFU)? More specifically, this is a non-comparative case series study and is subdivided into two major parts. Those parts are: Phase I: aimed at testing if, based on the IFU, the potential subjects can decide whether the study product is or is not appropriate to ...

Conditions: Xerostomia
Phase: Not Applicable

Iron Bioavailability From Cereal-based Foods

NCT05061290

Iron-deficient anemia is a chronic problem in sub-Saharan Africa and other developing areas of the world. From our previous research, we have shown that certain local plant foods in Kenya and Senegal have an unusual action of improving in vitro iron bioaccessibility (nearly doubling the low value obtained in cereals). We will assess absorption of stable isotopes of iron (57Fe, 54Fe and 58Fe) extrinsically labeled in a serving of porridge fortified with various combinations of moringa, baobab, ma ...

Conditions: Iron Bioavailability
Phase: Not Applicable

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

NCT05063539

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease

Conditions: Alzheimer Disease

A Study of ZL-1211 in Patients With Advanced Solid Tumor

NCT05065710

This study is a Phase I/II, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of ZL-1211 administered by IV infusion on a every 2 weeks (Q2W) schedule.

Conditions: Advanced Solid Tumor
Phase: Phase 1/2

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)

NCT05066230

This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).

Conditions: Non-proliferative Diabetic Retinopathy

Neural Basis of Sensory Learning: Brain Regions

NCT05079516

The purpose of this study is to understand how the sensory and motor areas of the brain work together to keep a person's hand movements accurate (sensorimotor learning). The investigators hope this information may be useful one day to improve rehabilitation techniques in patients with brain lesions.

Conditions: Basic Science
Phase: Not Applicable

Locomotor Recovery and Compensation Post-stroke (LRC)

NCT05081713

The proposed research will characterize of the time course of neurological and locomotor recovery as well as development of compensatory strategies throughout sub-acute and chronic phases post stroke. In addition, we will also investigate the extent to which measures of recovery and compensation are malleable and can be altered with specific interventions in both the early and late stages post-stroke. Delineation of the time course of development and magnitude of patterns of recovery and compens ...

Conditions: Stroke
Phase: Phase 1/2

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

NCT05083312

This is a randomized, double-blind, placebo-controlled study of APT-1011, followed by an open-label extension (OLE) in adolescents (≥12 to <18 years) with EoE.

Conditions: Eosinophilic Esophagitis

Adjunct Collection of Additional Biorepository Data From Patients Enrolled in Diabetic Foot Consortium (DFC) Trials

NCT05092620

The Biorepository will guide the Diabetic Foot Consortium (DFC) activities for collection and storing biosamples and data from participants enrolled in other current and future DFC research studies.

Conditions: Diabetic Foot Ulcer

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

NCT05093933

The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.

Conditions: Chronic Heart Failure With Reduced Ejection Fraction